• Flash Briefings and Podcasts

  Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA

  Posted by sma-news-today-moderator on March 16, 2020 at 11:05 am

  

  Anticipation is growing as Roche/Genentech’s treatment risdiplam, the first oral medication to treat SMA, is under FDA review.

  Also, SMA News Today’s multimedia associate, Price Wooldridge, discusses how the lack of SMA protein may also directly contribute to SMA.

  https://soundcloud.com/sma-news-today/risdiplam-under-fda-review-how-the-lack-of-sma-protein-may-also-directly-contribute-to-sma

  Are you interested in learning more about spinal muscular atrophy? If so, please visit smanewstoday.com/

  What are your thoughts on this news? Let us know about it in the comment section below.

  sma-news-today-moderator replied 4 years, 9 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply